Reports Q4 revenue $125.8M, consensus $132.7M. "We have significantly improved our liquidity profile with the removal of our CartiHeal obligations and the amendment of our debt agreement to provide covenant flexibility," commented Ken Reali, Bioventus’ chief executive officer. "Our results reflect additional pressure in our Pain Treatments vertical, primarily due to additional rebate claims previously not billed to us from a private payer, which offset the double-digit growth we are seeing in the Surgical Solutions vertical. Despite recent challenges, we maintain a strong, diversified business with market tailwinds and are focused on improving our execution and regaining investor confidence in 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BVS:
- Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
- Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
- Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
- Bioventus reschedules reporting of Q4, 2022 results
- Bioventus, Inc. (BVS) Q4 Earnings Cheat Sheet